Close
10/02/2016
New mechanism of anti-tumour action for the new drug developped at the UAB
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park, Barcelona Synchrotron Park partner), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.

The study, which has been published in the prestigious journal Clinical Cancer Research, was coordinated by Dr José Miguel Lizcano from the UAB Institute of Neurosciences and Department of Biochemistry and Molecular Biology.

Through the newly identified mechanism, ABTL0812 attacks tumour cells without affecting healthy cells, causing their death by autophagy without activating apoptosis (programmed cell death). It is the first anti-tumour drug to act in this way.

ABTL0812 has recently undergone Clinical Phase I trials in patients with advanced cancer, showing efficacy in several patients (long term stabilization) as well as low toxicity and high tolerability. Clinical Phase II trials are due to start soon in patients with endometrial cancer and lung squamous cell carcinoma.

More news

18/10/2017 The Sixth Ideas Generation Program Sponsored by the Barcelona Synchrotron Park Has Begun 12/10/2017 Barcelona Synchrotron Park's commitment to Biodiversity 02/10/2017 8 Congresses at the same time: it’s the Barcelona Industry Week! 26/09/2017 50th anniversary: congratulations UAB! 21/09/2017 More than 7,000 foreign companies in Catalonia 13/09/2017 How ALBA Synchrotron Works
14 15 16 17 18 19 20 21 22 23 24